Drug Trial Radar · NCT07361354
An Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Jan 5, 2026
Primary completion
Sep 5, 2026
Study completion Sep 5, 2026
Sponsor
- Lead sponsor
- Angitia Incorporated LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jan 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants
Conditions
- Healthy Participants
- Pharmacokinetic Study
Interventions
AGA2118Drug
Participants will receive AGA2118 administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum concentration (Cmax)Time frame: Day 1 to up to the end of study (85 days post-dose)
- Time to maximum concentration (Tmax)Time frame: Day 1 to up to the end of study (85 days post-dose)
- Area under the concentration-time curve (AUC)Time frame: Day 1 to up to the end of study (85 days post-dose)
- Half-life (t1/2)Time frame: Day 1 to up to the end of study (85 days post-dose)
- Clearance (CL)Time frame: Day 1 to up to the end of study (85 days post-dose)
- Volume of distribution (Vd)Time frame: Day 1 to up to the end of study (85 days post-dose)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Los Angeles EPCU
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.